KMPHARMACEUTICAL CEO Baek Seung-won Reports Share Reduction via Stock Merger, Ownership Stays at 1.68 Percent with Limited Shareholder Impact

KMPHARMACEUTICAL CEO Baek Seung-won reduced his shareholdings from 467,420 to 93,484 shares due to a stock merger effective May 19, 2026. The shareholder ratio remained unchanged at 1.68 percent as the total outstanding shares also decreased proportionally, resulting in no net impact on shareholder value.
The stock merger decreased total issued shares from 27,887,050 to 5,577,410 without any capital raising or dilution event. The CEO's ownership percentage remained constant, indicating a routine structural adjustment.
This filing is a mandatory disclosure of insider ownership changes and does not involve any additional capital activity such as convertible bonds or new share issuance. The merger solely consolidates share count.
[AI Summary]KMPHARMACEUTICAL CEO's stock merger triggered a proportional reduction in his share count with no change in ownership percentage, making this neutral for shareholder value. The adjustment is administrative with no capital allocation or governance risk.